文献速递基础与转化研究临床试验与 GCP

CD19 CAR-T细胞在B细胞淋巴瘤中持续存在长达十年

Decade-long persistence of CD19 CAR T cells in B cell lymphomas.
PubMed 文献 · Nat Med · 2026-08-10

该研究报告了38例非霍奇金淋巴瘤患者输注4-1BB共刺激抗CD19 CAR-T细胞(CART19)后长达10年的持续存在特征。超过5年时,8例长期缓解者中5例仍可检测到CAR19转基因(7.0-10.1年),3例维持B细胞再生障碍。持续存在的CART19细胞呈双阴性效应记忆样表型,伴代谢和活化程序增强,并显示寡克隆持续。

要点

  • CART19可在淋巴瘤患者体内持续超过10年,长期缓解者中可检测到转基因。
  • 持续存在的CART19以双阴性(CD4-CD8-)效应记忆样表型为主,伴代谢增强。
  • 随时间推移CAR-T细胞从CD8+向双阴性转变,呈寡克隆持续。

核心结论

  • CART19细胞可在B细胞淋巴瘤患者体内持续超过10年,并鉴定出与超长期持续相关的表型、转录和克隆特征。

研究设计与样本

  • 对38例接受4-1BB共刺激抗CD19 CAR-T细胞(CART19)治疗的非霍奇金淋巴瘤患者进行输注后长达10年的持续性和特征分析。

主要发现

  • 超过5年时,8例长期缓解者中5例可检测到CAR19转基因(7.0-10.1年),3例维持B细胞再生障碍。
  • 1例无进展生存10.1年的患者,输注后9.3年时CART19细胞占循环T细胞的1.2%。
  • 长期持续存在的CART19细胞以双阴性(CD4-CD8-)效应记忆样表型为主,伴需氧代谢增加和T细胞活化程序。
  • 纵向分析显示随时间推移从CD8+向双阴性CAR-T细胞逐渐转变。
  • T细胞受体测序显示9.3年时寡克隆持续,优势克隆(占CART19细胞70%)在14天时已以低频率(<0.1%)可检测到。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T cell therapy induces durable remissions in lymphoid malignancies, yet the extent and biology of long-term CAR T cell persistence in B cell lymphoma remain unclear. Here we report the persistence and characteristics of 4-1BB-costimulated anti-CD19 CAR T cells (CART19) up to 10 years after infusion in 38 patients with non-Hodgkin lymphoma. Beyond year five, the CAR19 transgene was detectable in five of eight long-term responders (7.0-10.1 years), with three patients maintaining B cell aplasia, which is consistent with sustained functional activity. In one patient with a progression-free survival of 10.1 years, CART19 cells comprised 1.2% of circulating T cells 9.3 years after infusion. Long-term persisting CART19 cells exhibited a predominant double-negative (CD4-CD8-), effector-memory-like phenotype associated with increased aerobic metabolism and T cell activation programs. Longitudinal profiling revealed a progressive transition from CD8+ to double-negative CAR T cells over time. Persisting CART19 shared transcriptional features with long-term CAR T cells described in acute and chronic leukemias. T cell receptor sequencing demonstrated oligoclonal persistence at 9.3 years, with a dominant clone (70% of CART19 cells) already detectable at low frequency (<0.1%) at day 14. Lentiviral integration-site analysis identified a predominant integration within PACS1 without evidence of known drivers of CAR T cell expansion. These findings demonstrate that CART19 cells can persist for more than 10 years in lymphoma and identify phenotypic, transcriptional and clonal features associated with exceptionally long-term persistence. ClinicalTrials.gov registration: NCT02030834.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Paruzzo L, Chong ER, Chong EA, et al. Decade-long persistence of CD19 CAR T cells in B cell lymphomas. Nat Med. 2026. PMID: 42575986. doi:10.1038/s41591-026-04578-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。